

## February 5, 2021 | Issue 158

Editor's note

This note is produced every Friday by the KPMG Center for Healthcare Regulatory Insight and is intended to be short and succinct, no more than 360 words, to provide a digestible bite of healthcare and life sciences news from the past week. Please share this email with colleagues and other interested individuals, and encourage them to subscribe to our mailing list here.

We welcome your feedback. Let us know if KPMG can help. Please <u>reply</u> here to me, Larry Kocot, principal and national leader, KPMG Center for Healthcare Regulatory Insight or simply reply to this email with any comments or requests.



## Special Supplement: COVID-19 News

In light of the continuing daily volume of COVID-19 activity and news, we have summarized COVID-19 news for the week in this special supplement.





## Healthcare regulatory news

HHS will <u>delay full implementation of the drug rebate rule</u> until January 2023; HHS must decide whether to defend the regulation by April 1.

FDA <u>delayed until June 7</u> an approval decision for Biogen's Alzheimer's treatment... FDA appointed the first <u>Acting Director of Medical Device</u> Cybersecurity.

President Biden signed an <u>Executive Order directing federal agencies</u> to review the "public charge" rule and develop policies to promote integration, inclusion, and citizenship.

The Biden Administration asked federal courts for 60-day pauses for lawsuits over <u>association health plans</u> and <u>drug importation</u> while it reviews the cases.





## Healthcare law and policy news

McKinsey will pay \$573M to settle opioid crisis-related claims... A district court threw out Walmart's lawsuit attempting to preempt federal government claims over its role in the opioid crisis... The Supreme Court scheduled oral arguments for Medicaid work requirement cases on March 29.

Venture capitalists <u>invested a record \$52B</u> in healthcare companies last year, up 50% from 2019...Horizon Therapeutics <u>will acquire Viela Bio</u> (\$3.05B)... Jazz Pharmaceuticals <u>will acquire GW Pharmaceuticals</u> (\$7.2B)... Gilead will <u>collaborate with Gritstone Oncology</u> on an HIV vaccine-based immunotherapy... Anthem will <u>acquire InnovaCare MA and Medicaid plans</u> in Puerto Rico... 23andMe <u>will merge with a Virgin Groupsponsored SPAC</u> to go public.

University Hospitals and Case Western Reserve University <u>extended their affiliation through 2031</u>... Humana will <u>partner with DispatchHealth</u> to provide hospital-level care in members' homes... <u>Geisinger and Children's Hospital of Philadelphia</u> will affiliate... Kaiser Permanente will <u>partner with Microsoft and Accenture</u> to improve cloud capabilities.

Uber <u>launched a prescription delivery service</u> in NYC with Nimble... Research shows the <u>Apple Watch can be used to monitor Parkinson's</u> disease symptoms.

AHA urged the Acting FTC Chair and Acting CMS Administrator to review UnitedHealth Group policies impacting patient costs/coverage... MGMA and Humana reported that 97% of physician practices had patient volume drop by early April due to COVID-19... Health Affairs studies found that people enrolling in higher star-rated MA plans experience a 3.4% increase in use of highly-rated hospitals and 2.6% reduction in 90-day readmissions

and that nearly 40% of commercially insured individuals incurred <u>half of</u> their annual out-of-pocket spending in one healthcare encounter.

MACPAC recommended <u>Congress automatically boost Medicaid federal</u> <u>funding (FMAP)</u> during recessions.





Questions or comments, please send to <u>us-hcinsight@kpmg.com</u>.

# Succeeding in the new reality

Visit the COVID-19 resource center for KPMG analysis, insights, and perspectives.



#### kpmg.com/socialmedia











### Privacy | Legal

You have received this message from KPMG LLP. If you wish to unsubscribe from Around the world of U.S. healthcare in 360 words or less, please click here. If you wish to unsubscribe from all KPMG communications, please click here.

KPMG LLP, 3 Chestnut Ridge Road, Montvale, NJ 07645

© 2021 KPMG LLP, a Delaware limited liability partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved. NDP131714-1A

The KPMG name and logo are trademarks used under license by the independent member firms of the KPMG global organization.



## COVID-19 by the Numbers

There are now over 26.6 million confirmed COVID-19 cases in the US, with a <u>death toll over 455,000</u>... The US averaged <u>139,000 new cases/day</u> over the last week, down 16% from the week before; hospitalizations were down 26%; deaths were down 6% to 3,097/day... A <u>meta-analysis found</u> that the mortality rate for COVID-19 patients admitted to ICUs has reduced or plateaued since May 2020... A <u>Science study estimated</u> that 65% of new COVID-19 infections originated from adults aged 20-49 through mid-August of 2020.

36.7 million COVID-19 vaccine doses have been administered in the US, 64% of total doses distributed to states... Initial CDC data show that race and ethnicity data is only available for about half of COVID-19 vaccines administered nationwide and that 60.4% of individuals vaccinated were White, 14.4% were multiple races or ethnicities, 11.5% were Hispanic, 6% were Asian, and 5% were Black, and 2% were American Indian or Alaska Natives... CDC data (accessed 2/5/2021) show that over 4.2M doses have been administered through the Federal Pharmacy Partnership for Long-Term Care Program and almost 800,000 residents have received 2 doses.

## Executive and Administrative Action

The Biden Administration will begin shipping COVID-19 vaccines directly to retail pharmacies, beginning with 1 million doses to roughly 6,500 pharmacies per week; 40,000 pharmacies could eventually be included... the Administration <u>urged health care providers to stop stockpiling COVID-19 vaccines</u> and to use all available vaccines as soon as possible... President Biden is <u>seeking \$4 billion to build and equip two vaccine manufacturing facilities</u> capable of producing 100 million COVID-19 vaccine doses per month.

The Biden Administration will use the Defense Production Act to increase supplies needed for manufacturing of Pfizer's COVID-19 vaccine and to increase availability of at-home COVID-19 tests.

Coronavirus response coordinator Jeff Zients said that states will be fully reimbursed for eligible emergency resources and services, such as masks, gloves, and National Guard mobilization, purchased or provided since the beginning of the pandemic.

CDC <u>issued a public health order</u> requiring face coverings on airplanes, trains, and other public transportation... CDC Director Rochelle Walensky said that <u>vaccinating teachers should not be a prerequisite</u> for reopening schools.

President Biden <u>declared that a major disaster exists for the Navajo Nation</u> related to COVID-19 and ordered additional federal assistance.

HHS and the Defense Department <u>will invest \$231.8M to increase production</u> of Ellume's at-home COVID-19 test.

Axios reported that Trump Administration <u>officials urged Congress last fall to not give states any</u> additional funding to support COVID-19 vaccine rollout.

Texas will <u>require providers administering COVID-19 vaccines</u> to report race and ethnicity of vaccine recipients within 24 hours or potentially have vaccine allocations cut.

## Healthcare Regulatory News

FDA is <u>limiting emergency use authorization for convalescent plasma treatment</u> to hospitalized patients in the early stages of a COVID-19 infection.

FDA is <u>developing new standards</u> for COVID-19 booster shots, tests, and therapeutics in order to respond to rapidly spreading virus variants.

OSHA released revised workplace COVID-19 safety guidelines.

## Healthcare Law, Business, and Policy News

President Biden met with 10 Senate Republicans to <u>discuss their plan for a \$618M COVID-19 relief</u> <u>package</u>, later telling Congressional Democrats <u>that the Republican plan was "way too small"</u>... Biden indicated he is open to some changes to his \$1.9 trillion plan, such as limiting who gets stimulus payments, but <u>urged Democrats to "act fast" and "go big"</u>... The <u>House</u> and <u>Senate</u> passed respective budget resolutions beginning a budget reconciliation process to pass their relief package; the Senate <u>approved an amendment</u> to replenish the Provider Relief Fund by \$35 billion... A Quinnipiac poll found that <u>68% of Americans support</u> the \$1.9 trillion relief plan.

State officials told the House Energy and Commerce Oversight subcommittee that they need significantly more funding to speed up vaccine rollout and better predictability about how many vaccines they'll receive each week.

An Axios-Ipsos poll found that <u>83% of Americans are concerned</u> that new COVID-19 strains may be more transmissible and 65% do not expect to "get back to something like their normal, pre-COVID life" for at least 6 months.

A JAMA study found that <u>ED use shifted during the pandemic</u>, with higher emergency-room visits for mental health conditions, suicide attempts, drug overdoses, intimate partner violence, and child abuse/neglect than over the same period in 2019.

Google Cloud <u>launched AI and machine learning tools</u> to help organizations forecast and model COVID-19 cases for vaccine allocation decision-making... Optum reported that it <u>accidentally charged 249 Medicare Advantage enrollees</u> for the COVID-19 vaccine.

More than 40 business groups asked the US Equal Employment Opportunity Commission to clarify what kinds of incentives employers can legally offer to encourage COVID-19 vaccinations... Consumer Federal of America urged life insurers to establish clear and transparent rules on life insurance eligibility and COVID-19.

## Surveillance, Testing, and Treatment

Johnson & Johnson <u>applied for emergency use authorization</u> for its one-shot COVID-19 vaccine... FDA's Vaccines and Related Biological Products Advisory Committee <u>will meet on February 26<sup>th</sup></u> to review the request.

Pfizer and BioNTech plan to <u>make at least 2 billion doses of their COVID-19 vaccine</u> this year, up from previous estimates of 1.3B... Pfizer <u>forecasts \$15 billion</u> in 2021 COVID-19 vaccine revenue... Pfizer is planning to <u>test whether administering a third dose</u> of its COVID-19 vaccine administered between 6-12 months after the initial dose will increase protection against new virus strains.

NPR reported that Moderna and Pfizer-BioNTech will <u>need to increase weekly deliveries of their COVID-19 vaccines</u> in order to meet their commitments to provide 100 million doses each to the federal government by March 31... Moderna is <u>seeking FDA approval to fill empty capacity</u> in its COVID-19 vaccine vials with as many as 50% more doses.

The European Medicines Agency granted conditional marketing authorization for the AstraZeneca-Oxford vaccine for adults over the age of 18... Wall Street Journal reported on significant AstraZeneca COVID-19 vaccine production issues... Oxford University researchers reported that its COVID-19 vaccine with AstraZeneca is 82.4% effective with a 12-week gap between the two doses... AstraZeneca and Oxford aim to produce a "next generation" vaccine to protect against new variants as soon as this fall.

University of Oxford will begin a trial combining COVID-19 vaccines from AstraZeneca and Pfizer.

Novartis will <u>support manufacturing</u> of the Pfizer-BioNTech COVID-19 vaccine... GlaxoSmithKline will produce up to 100 million doses of a CureVac COVID-19 vaccine candidate.

Novavax announced that multiple regulatory agencies have begun <u>rolling reviews of its COVID-19</u> vaccine.

A phase 3 trial found that the <u>Russian-developed Sputnik V vaccine is 91.6% effective</u> in protecting against COVID-19.

COVAX plans to <u>distribute more than 337 million COVID-19 vaccine doses</u> to developing nations between the end of February and June 2021.

Bristol Myers Squibb will <u>develop Rockefeller University's novel COVID-19 monoclonal antibody</u> treatment.